Online citations, reference lists, and bibliographies.
← Back to Search

Gene Expression Profiling Predicts Clinical Outcome Of Breast Cancer

L. J. Veer, H. Dai, M. Vijver, Yudong D. He, A. Hart, M. Mao, H. Peterse, K. V. D. Kooy, M. Marton, A. Witteveen, G. Schreiber, R. Kerkhoven, C. Roberts, P. Linsley, R. Bernards, S. Friend
Published 2002 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Breast cancer patients with the same stage of disease can have markedly different treatment responses and overall outcome. The strongest predictors for metastases (for example, lymph node status and histological grade) fail to classify accurately breast tumours according to their clinical behaviour. Chemotherapy or hormonal therapy reduces the risk of distant metastases by approximately one-third; however, 70–80% of patients receiving this treatment would have survived without it. None of the signatures of breast cancer gene expression reported to date allow for patient-tailored therapy strategies. Here we used DNA microarray analysis on primary breast tumours of 117 young patients, and applied supervised classification to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis (lymph node negative). In addition, we established a signature that identifies tumours of BRCA1 carriers. The poor prognosis signature consists of genes regulating cell cycle, invasion, metastasis and angiogenesis. This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy.
This paper references
10.1093/JNCI/83.3.154
Breast cancer prognostic factors: evaluation guidelines.
W. L. McGuire (1991)
10.1200/JCO.2002.20.7.1955
Meeting highlights: international consensus panel on the treatment of primary breast cancer.
A. Goldhirsch (2002)
10.1002/GCC.2870140402
Genetic alterations in breast cancer
I. Bièche (1995)
10.1038/382678A0
Transcriptional activation by BRCA1
M. Chapman (1996)
Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.
P. V. van Diest (1997)
10.1016/S0140-6736(97)11423-4
Tamoxifen for early breast cancer: an overview of the randomised trials
O Abe (1998)
10.1016/S0140-6736(98)03301-7
Polychemotherapy for early breast cancer: an overview of the randomised trials
M. Clarke (1998)
10.1093/JNCI/90.15.1138
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
S. Lakhani (1998)
Polychemotherapy for early breast cancer: An overview of the randomised trials
O. Abe (1998)
10.1073/PNAS.96.16.9212
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.
C. Perou (1999)
10.1186/bcr274
Molecular profiling of breast cancer: portraits but not physiognomy
J. Brenton (2000)
10.1093/JNCI/92.7.564
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
M. Esteller (2000)
10.1126/SCIENCE.287.5454.873
Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles.
C. J. Roberts (2000)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
Linking gene expression patterns to therapeutic groups in breast cancer.
K. Martin (2000)
National institutes of health consensus development conference statement: adjuvant therapy for breast cancer
P Eifel (2000)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1073/pnas.171174298
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
L. Zheng (2001)
10.1038/89044
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
J. Khan (2001)
10.1038/89022
Microarrays—the 21st century divining rod?
Yudong D. He (2001)
10.1038/86730
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer
T. Hughes (2001)
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
S. Gruvberger (2001)
10.1093/JNCI/93.12.913
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
F. Jänicke (2001)
Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells.
D. Zajchowski (2001)
10.1056/NEJM200102223440801
Gene-expression profiles in hereditary breast cancer.
I. Hedenfalk (2001)
10.1073/pnas.201162998
Predicting the clinical status of human breast cancer by using gene expression profiles
M. West (2001)
10.1093/JNCI/93.13.979
National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
P. Eifel (2001)
Gene-expression pro®les in hereditary breast cancer
I Hedenfalk (2001)
Identi®cation of gene expression pro®les that predict the aggressive behavior of breast cancer cells
D A Zajchowski (2001)
Classi®cation and diagnostic prediction of cancers using gene expression pro®ling and arti®cial neural networks
J Khan (2001)
10.1038/nm0102-68
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
M. Shipp (2002)
10.1038/415536a
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
10.1023/A:1006102916060
Cyclins and breast cancer
P. Steeg (2004)
Competing interests statement The authors declare competing ®nancial interests: details accompany the paper on Nature's website
VOL 415 | 31 JANUARY 2002 | www.nature.com Supplementary Information accompanies the paper on Nature's website (http://www.nature.com)
.
Correspondence and requests for materials should be addressed to S.H.F. (e-mail: stephen_friend@merck.com)



This paper is referenced by
10.1016/b978-0-12-821666-8.00015-3
MicroRNAs and bone metastasis
(2022)
10.1016/b978-0-12-819869-8.00029-x
Biomarkers in drug development
Robert N. Schuck (2022)
10.1016/j.jare.2020.11.006
A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models
Yi-Wen Hsiao (2020)
10.1186/s40364-021-00292-x
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
C. Viet (2021)
10.1097/PAI.0000000000000909
L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer: A Novel Biomarker Worth Considering
I. Moisini (2021)
10.3390/cancers13184544
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Nuria Gómez-Cebrián (2021)
The Age-Dependent Characterization of the ER-Alpha Positive Breast Cancer Tumor Microenvironment
K. Hamel (2021)
10.1007/s10911-021-09484-5
A Method to Pre-Screen Rat Mammary Gland Whole-Mounts Prior To RNAscope
Emily L. Duderstadt (2021)
Outcome-guided Bayesian Clustering for Disease Subtype Discovery Using High-dimensional Transcriptomic Data
Lingsong Meng (2021)
10.1007/978-3-030-73147-2_50
Planning Adjuvant Treatment
Vasileios Barmpounis (2021)
10.1038/s41588-021-00903-1
A call for direct sequencing of full-length RNAs to identify all modifications.
J. Alfonzo (2021)
10.1101/2021.05.07.442940
Benchmarking 50 classification algorithms on 50 gene-expression datasets
Stephen R. Piccolo (2021)
10.21873/anticanres.14791
Dosimetric Impact of Respiratory Motion During Breast Intensity-modulated Radiation Therapy Using Four-dimensional Dose Calculations
Y. E. Choi (2021)
10.21203/rs.3.rs-829187/v1
Tumor Cell Intrinsic And Extrinsic Features Predicts Prognosis In Estrogen Receptor Positive Breast Cancer
Kevin Yao (2021)
10.1007/978-3-030-47189-7_2
HGF/c-Met Signalling in the Tumor Microenvironment.
A. Zambelli (2021)
Outcome-guided Sparse K-means for Disease Subtype Discovery via Integrating Phenotypic Data with High-dimensional Transcriptomic Data
Lingsong Meng (2021)
10.1182/blood.2019004259
Cohesin mutations in myeloid malignancies.
Joahnn-Christoph Jann (2021)
10.3389/fgene.2021.687813
Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer
Christina Y. Yu (2021)
10.1016/J.PATCOG.2021.108066
A deep fusion framework for unlabeled data-driven tumor recognition
Xiaohui Yang (2021)
10.3390/cancers13194907
Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer
T. T. Do (2021)
10.1038/s41388-021-01970-8
Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation
Shaoyang Zhang (2021)
10.3389/fcvm.2021.648910
Vagus Nerve Stimulation in Early Stage of Acute Myocardial Infarction Prevent Ventricular Arrhythmias and Cardiac Remodeling
Shuang Zhao (2021)
10.1007/s10549-021-06328-y
Increased gene expression variability in BRCA1-associated and basal-like breast tumours
George A. R. Wiggins (2021)
10.1007/S11831-021-09556-Z
A Systematic Review of Applications of Machine Learning in Cancer Prediction and Diagnosis
Aman Sharma (2021)
10.1093/bioinformatics/btab145
NIBNA: a network-based node importance approach for identifying breast cancer drivers
M. S. Chaudhary (2021)
10.1007/s10549-021-06315-3
Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer
J. L. Lopes Cardozo (2021)
10.1016/j.ejca.2021.04.016
Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Seodhna M Lynch (2021)
10.1021/acsami.1c11953
Dual-Multivalent-Aptamer-Conjugated Nanoprobes for Superefficient Discerning of Single Circulating Tumor Cells in a Microfluidic Chip with Inductively Coupled Plasma Mass Spectrometry Detection.
Xuan Zhang (2021)
10.1038/s41419-021-04060-5
Aberrant super-enhancer-driven oncogene ENC1 promotes the radio-resistance of breast carcinoma
Lin Li (2021)
10.1016/j.breast.2021.05.010
The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
E. Myburgh (2021)
10.1016/j.csbj.2021.07.003
Machine learning in the prediction of cancer therapy
R. Rafique (2021)
10.1007/s11033-021-06797-w
Targeted and systemic insights into the crosstalk between DNA-dependent protein kinase catalytic subunit and receptors of estrogen, progesterone and epidermal growth factor in the context of cancer.
Soubiya Mohammed Rizwan Ansari (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar